ASH 2023 | Blinatumomab and ponatinib in newly diagnosed Ph+ ALL: updates from a Phase II trial
Fadi Haddad, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the updates from the Phase II trial of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) (NCT03263572). This treatment regimen eliminated the need for hematopoietic stem cell transplantation (SCT) by inducing measurable residual disease (MRD)-negativity in a large number of patients and producing promising data for overall survival (OS) and length of remission. Dr Haddad also comments on which patients were most at risk of central nervous system (CNS) relapse and how the protocol was amended to try to prevent this. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
